Relationship of medical therapy and survival in patients after acute cardiogenic pulmonary oedema;Wpływ leczenia farmakologicznego na rokowanie krótkoterminowe i długoterminowe u pacjentów po incydencie kardiogennego obrzeku płuc

Polski Przeglad Kardiologiczny

Volumn 5, Issue 4, 2003, Pages 409-414

  Fiutowski, Marcin ^a   Waszyrowski, Tomasz ^a   Krzemińska Pakuła, Maria ^b   Kasprzak, Jarosław D ^b  

^a Szpitala Miejskiego ^*  (Poland)

^b Klinika Kardiologii Inst Med   (Poland)

Author keywords

Heart failure; Medical therapy; Prognosis; Pulmonary oedema

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; CATECHOLAMINE DERIVATIVE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCERYL TRINITRATE; HEPARIN; MORPHINE; NITRIC ACID DERIVATIVE; STEROID;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOLOGY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HOSPITAL ADMISSION; HOSPITAL DEPARTMENT; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LONG TERM CARE; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTPATIENT CARE; PROGNOSIS; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; TREATMENT PLANNING; UNSTABLE ANGINA PECTORIS; VALVULAR HEART DISEASE;

EID: 0345874694     PISSN: 15075540     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Cleland J.G.F., Cohen-Solal A., Cosin Aguilar J. i wsp.: Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet, 2002, 360, 1631-1639.
2. Fiutowski M., Waszyrowski T.: Kardiogenny obrzek pluc - patofizjologia, leczenie i rokowanie. Forum Kardiologów, 2001, 6, 105-110.
3. Kjaer A., Hesse B.: Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives. Clin. Physiol., 2001, 21, 661-672.
4. Rubin W., Kosmala W., Kobusiak-Prokopowicz M.: Neurohumoral mechanisms in pathophysiology of chronic heart failure. Przegl. Lek., 2000, 57, 750-756.
5. Richards A.M., Nicholls M.G., Yandle T.G. i wsp.: Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. The Christchurch Cardioendocrine Research Group. Heart, 1999, 81, 114-120.
6. Willenbrock R., Philipp S., Mitrovic V., Dietz R.: Neurohumoral blockade in CHF management. J. Renin. Angiotensin Aldosterone Syst., 2000, 1, supl. 1, 24-30.
7. Ferrara R., Mastrorilli F., Pasanisi G. i wsp.: Neurohormonal modulation in chronic heart failure. Eur. Heart J., 2002, 4, supl. D, D3-D11.
8. De Boer R.A., van Veldhuisen D.J.: Polypharmacy in chronic heart failure: practical issues regarding the use of angitensin-converting enzyme inhibitors, beta-blockers and other drugs. Eur. Heart J., 2002, 4, supl. D, D111-D116.
9. Fuchs M., Drexler H.: Pharmacotherapy of chronic heart failure: current status and future aspects. Eur. Heart J., 2002, 4, supl. 1, I81-I87.
10. Zannad F.: Evidence-based drug therapy for chronic heart failure. Eur. Heart J., 2002, 4, supl. D, D66-D72.
11. Swynghedauw B., Chariemagne D.: What is wrong with positive inotropic drugs? Lessons from basic science and clinical trials. Eur. Heart J., 2002, 4, supl. D, D43-D49.
12. Levy D., Kenchaiah S., Larson M.G. i wsp.: Long-term trends in the incidence of and survival with heart failure. N. Engl. J. Med., 2002, 347, 1397-1402.
13. Edoute Y., Roguin A., Behar D., Reisner S.A.: Prospective evaluation of pulmonary edema. Crit. Care Med., 2000, 28, 330-335.
14. Le Conte P., Coutant V., N'Guyen J.M. i wsp.: Prognostic factors in acute cardiogenic pulmonary edema. Am. J. Emerg. Med., 1999, 17, 329-332.
15. Brezins M., Benari B., Papo V. i wsp.: Left ventricular function in patients with acute myocardial infarction, acute pulmonary edema, and mechanical ventilation: relationship to prognosis. Crit. Care Med., 1993, 21, 380-385.
16. Sacchetti A., Ramoska E., Moakes M.E. i wsp.: Effect of ED management on ICU use in acute pulmonary edema. Am. J. Emerg. Med., 1999, 17, 571-574.
17. Cotter G., Metzkor E., Kaluski E. i wsp.: Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet, 1998, 351, 389-393.
18. Sharon A., Shpirer I., Kaluski E. i wsp.: High-dose intravenous isosorbide-dinitrate is safer and better than Bi-PAP ventilation combined with conventional treatment for severe pulmonary edema. J. Am. Coll. Cardiol., 2000, 36, 832-837.
19. Hamilton R.J., Carter W.A., Gallagher E.J.: Rapid improvement of acute pulmonary edema with sublingual captopril. Acad. Emerg. Med., 1996, 3, 205-212.
20. Annane D., Bellissant E., Pussard E. i wsp.: Placebo-controlled, randomized, double-blind study of intravenous enalaprilat efficacy and safety in acute cardiogenic pulmonary edema. Circulation, 1996, 94, 1316-1324.
21. CIBIS II Investgators and Cimmittees: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet, 1999, 353, 9-3.
22. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Head Failure (MERIT-HF). Lancet, 1999, 353, 2001-2007.
23. Dargie H.J.: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet, 2001, 357, 1385-1390.
24. Packer M., Coats A.J., Fowler M.B. i wsp.: Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med., 2001, 344, 1651-1658.
25. The Digitalis Investigation Group: The effect of digoxin on mortality and morbidity in patients with heart failure. N. Engl. J. Med., 1997, 336, 525-533.